The successful sale of ZimVie’s spine division to investment firm H.I.G. Capital...
First, due to the burden on its patients and healthcare infrastructure, and now ...
Despite a setback when the FDA denied its first effort at clearance for Vafseo, ...
With Regeneron’s desire to move its blood cancer medicine odronextamab from fift...
As a therapy for two uncommon illnesses, ulcerative colitis (UC) and multiple sc...
Regeneron’s hasty submission of the bispecific antibody odronextamab to regulato...
As anticipated this week, the FDA is poised to authorize Merck’s pioneering trea...
Olympus has joined forces with the American Lung Association (ALA) to raise awar...
Johnson Matthey, a British corporation specializing in metals and chemicals, is ...
Twelve years after the FDA initially granted limited approval to Takeda’s Iclusi...
Novo Nordisk, a prominent player in the pharmaceutical industry, is commemoratin...
Hippocratic AI emerged from stealth mode approximately a year ago, unveiling its...
Bayer’s recent announcement regarding its intention to seek regulatory approval ...
AstraZeneca has made a strategic move into the realm of rare endocrinology with ...
AstraZeneca’s decision to integrate Fusion Pharmaceuticals into its cancer divis...
A comprehensive series of sophisticated examinations conducted by researchers re...
